Cogent Biosciences Overview
Get informed when a big investor buys or sells
+ Follow-12.31
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Cogent Biosciences (COGT) currently reports a P/E ratio of -12.31. That is below the Healthcare sector average of 21.65. Use the charts on this page to explore Cogent Biosciences's P/E ratio history and peer comparisons.
Cogent Biosciences's P/E ratio of -12.31 is lower than the Healthcare sector average of 21.65. That is roughly 156.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Cogent Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At -12.31, COGT can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -12.31, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.65. From there, open related valuation or income-statement pages for Cogent Biosciences, and consider following COGT for alerts when major investors trade the stock.
Cogent Biosciences is classified in the Healthcare sector. On P/E ratio, it currently shows -12.31 versus a sector average near 21.65. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing COGT with unrelated industries.
